L3VLUP
ProSign in

WAT · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

WATVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • WAT
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterWATVRTX
Q3 202022 holders, $1.9bn31 holders, $21.9bn
Q4 202017 holders, $2.1bn30 holders, $18.4bn
Q1 202115 holders, $2.2bn31 holders, $15.4bn
Q2 202116 holders, $2.5bn30 holders, $12.7bn
Q3 202118 holders, $2.8bn35 holders, $10.1bn
Q4 202114 holders, $3.1bn28 holders, $12.4bn
Q1 202217 holders, $2.4bn23 holders, $16.1bn
Q2 202218 holders, $2.7bn25 holders, $18.1bn
Q3 202219 holders, $2.2bn22 holders, $18.4bn
Q4 202221 holders, $2.5bn28 holders, $18.4bn
Q1 202323 holders, $2.5bn26 holders, $21.4bn
Q2 202315 holders, $2.3bn27 holders, $24.7bn
Q3 202314 holders, $2.4bn33 holders, $24.3bn
Q4 20238 holders, $2.6bn32 holders, $28.6bn
Q1 20248 holders, $2.8bn31 holders, $29.8bn
Q2 202410 holders, $2.1bn29 holders, $33.4bn
Q3 20247 holders, $2.5bn27 holders, $33.5bn
Q4 202410 holders, $2.8bn26 holders, $28.5bn
Q1 202511 holders, $3.1bn21 holders, $35.4bn
Q2 202512 holders, $3.3bn21 holders, $32.3bn
Q3 202512 holders, $2.6bn22 holders, $25.9bn
Q4 202515 holders, $3.9bn26 holders, $31.8bn
Q1 202618 holders, $6.6bn25 holders, $31.8bn
Q2 202620 holders, $9.8bn26 holders, $34.6bn
WAT

Waters Corp

Holders
8
Reported value
$2.8bn
Buyers
2
Sellers
6

Breadth -4 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
31
Reported value
$29.8bn
Buyers
16
Sellers
19

Breadth -3 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only WAT (1)

Baillie Gifford & Co

Only VRTX (24)

Acadian Asset Management LLC, AQR Capital Management LLC, ARK Investment Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., ExodusPoint Capital Management LP, Fidelity (FMR LLC), Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Voloridge Investment Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →